7148 DPHARMA | Malaysia
DUOPHARMA BIOTECH BERHAD
RM 3.54 on: 2021-01-15
-3.54% Past 1-day return
+7.93% Past 5-day return
Price/Valuation Analysis
Current Price Status
-
Stock is in Momentum
Stock is currently overvalued by the market with the expectation of annual earning growth at 44.72% to match current price.
Overvalued stock can be traded very volatile. If the earning growth momentum continue, overvalued stock can match into fair value, on the flip side, the downside risk can be huge if the stock is not meeting the market expectation. -
Company is in Positive Earning
Fair Value
- DPHARMA current price is 12.74% above OneDelta estimated fair value.
-
The fair value is estimated via OneDelta proprietary model that updated daily basis based on stock fundamental and specific industry relative marco outlook. It can be assessed as stock potential upside range or the stock true value price in case of downside.
Relative Price Performance
-
Outperformed
DPHARMA past 5-day return perform better than Pharmaceuticals industry average return by 2.47% -
Above 30-Day Average
Current price RM3.54 is above than 30-day average RM3.5 by 1.1%
| Return (%) | DPHARMA | Pharmaceuticals |
|---|---|---|
| 1-Day | -3.54% | -0.24% |
| 5-Day | +7.93% | +5.46% |
| 30-Day | -6.35% | -2.51% |
Bank Analyst Price Targets
Revenue & Earning Growth Analysis
-
Recent Weak Revenue Growth
DPHARMA posted a weaker revenue growth in the recent quarter than normal average.
-
Unstable Profit Growth
DPHARMA has been experiencing substantial ups and downs on profit growth.
Past Quarter Reports
| Quarter Date | Revenue (RM) | (%) | EPS (RM) | (%) |
|---|---|---|---|---|
| 2020-09-30 | 133,772k | -7% | 0.0203 | -6% |
| 2020-06-30 | 143,331k | -10% | 0.0215 | +9% |
| 2020-03-31 | 158,713k | +15% | 0.0198 | +13% |
| 2019-12-31 | 137,755k | -4% | 0.0176 | -20% |
| 2019-09-30 | 142,855k | -2% | 0.022 | +6% |
Volume Trend Analysis
-
Recent Volume is Increasing
Surge in trading volume tends to bring more price volatility in near term.
-
DPHARMA recent daily traded volume is 29.79% higher than past month average.
| Past 30-Day | Past 5-Day |
|---|---|
| 47k daily | 61k daily |
Financials
Price History Chart
Past 30-day Average Price: RM3.5
Stock Fundamental Factors
Fundamental factor characteristics help us understand and expect how the stock price will behave in short and long term.
Stock Thematic Baskets
Usually the more the stock is included in popular themes, the more opportunity for price-driven momentum and better liquidity.
Market News & Investor Opinions
RHB Research upgrades Duopharma to 'buy', raises target price to RM4
RHB Research upgrades Duopharma to Buy with RM4 target price
Duopharma gets one-year extension for supply of human insulin products
Duopharma Biotech gets deal extension
Duopharma Biotech added to Dow Jones Islamic Market Index
Duopharma cautiously optimistic on full-year results
Duopharma makes RM14.2mil net profit in Q3
Duopharma Biotech 3Q net profit down 5% on lower demand from private sector
Duopharma to partner with OEM in Indonesia, Singapore
Duopharma stock rises as EPF increases stake
Stock Company Profile
DUOPHARMA BIOTECH BERHAD
Duopharma Biotech Bhd. is an investment holding company, which engages in the research, development, and commercialization of chemical and pharmaceutical products. Its products include tablets, capsules, syrup, antibiotic, creams, haemodialysis solution, sterile irrigation solution, sterile powder injectibles, small volume injectibles, dental cartridges, and eye drop preparations. The company was founded in 1979 and is headquartered in Klang, Malaysia.